Drug Discovery

Resumen del seminario web: Un análisis basado en patentes sobre hacia dónde se dirige la innovación farmacéutica, desde la diversificación de las modalidades terapéuticas y la expansión de las dianas moleculares hasta las áreas de enfermedades donde la investigación se está acelerando.

La inmunoterapia está impulsando la oncología de precisión, pero los tratamientos de inmunooncología existentes no son efectivos para todos los pacientes. Nuestra revisión del panorama de la investigación traslacional revela qué objetivos y terapias están mostrando resultados prometedores en ensayos clínicos.

Cinco años de datos globales de patentes farmacéuticas revelan un sector en transición fundamental: las plataformas terapéuticas se multiplican, los objetivos moleculares se expanden mucho más allá de las proteínas tradicionales y el enfoque de las enfermedades se desplaza hacia afecciones anteriormente intratables. Los patrones muestran no solo dónde se concentra la innovación

Los péptidos cíclicos están mejorando los tratamientos para el cáncer, las enfermedades inflamatorias e infecciosas, y más, a medida que se mejoran los métodos de administración oral.

Los espiro[2.3]hexanos son un ejemplo de estructuras de andamiaje prometedoras pero desafiantes para nuevos compuestos farmacológicos. Mediante el uso de análisis predictivo basado en inteligencia artificial con CAS BioFinder, los investigadores identificaron candidatos para su validación de manera más eficiente.

CAS organizó cumbres de ciencias de la vida en tres regiones en 2025, explorando la integración práctica de la inteligencia artificial en el descubrimiento de fármacos. Conozca más sobre la gobernanza de datos, las barreras de implementación y los desafíos específicos de cada modalidad.

Desde los avances en microbiomas hasta las simulaciones basadas en IA, este resumen del seminario web de CAS Insights explora las últimas tendencias en el descubrimiento de fármacos que están cambiando la investigación farmacéutica.

El enfoque teranóstico de la medicina nuclear permite la terapia oncológica de tipo «verlo y tratarlo» con mismos agentes para diagnóstico y tratamiento. La inversión se triplicó hasta los 14 860 millones de USD en 2024, conforme estos tratamientos de precisión avanzan hacia la atención temprana.

Explore eight leading trends in drug discovery that are improving cancer treatment, identifying neurodegenerative conditions, and even preparing for a future pandemic

Dado que muchos catalizadores y reactivos son sensibles a la humedad, el agua solía excluirse como disolvente potencial. Ahora, parece que muchas transformaciones orgánicas pueden lograrse en agua o sobre agua sin utilizar productos químicos nocivos ni compuestos orgánicos volátiles como disolventes.

Las células MAIT son un descubrimiento relativamente nuevo en comparación con otros tipos de células T no convencionales, y los investigadores están avanzando en su uso como inmunoterapias "listas para usar".

La terapia con células madre podría curar la diabetes

Nuevos avances en la terapia génica con microARN

Vea un avance de nuestro nuevo informe sobre DDS basados en lípidos

¿Cómo podrían las vacunas de ARNm revolucionar la lucha contra enfermedades más allá de la COVID-19?

Una infografía proporciona detalles sobre los agonistas del receptor GLP-1 y los fármacos polipeptídicos GIP para la pérdida de peso.

Los inhibidores de IPP de moléculas pequeñas están a punto de mejorar los tratamientos contra el cáncer

Los PROTAC están impulsando el desarrollo de fármacos de moléculas pequeñas para tratar el cáncer, las enfermedades neurodegenerativas y más

Descubra cómo CAS aprovecha la gestión avanzada de datos y los modelos predictivos para revolucionar el descubrimiento de fármacos en esta conversación con líderes de la industria.

Aunque la terapia celular CAR-T se utiliza principalmente para el cáncer, ha mostrado resultados prometedores en el tratamiento de enfermedades autoinmunes, VIH y más

La función de GIP y GLP-1 muestra resultados prometedores en el tratamiento de afecciones cardiovasculares y neurodegenerativas.

Nanoscale drug delivery systems can improve treatment for cancer, autoimmune diseases, HIV, and other conditions

Cómo las terapias combinadas, como la reutilización de fármacos, la terapia celular y la terapia génica, están mejorando el tratamiento de las enfermedades raras.

Biomarkers, personalized medicine and gene therapies are fueling research breakthroughs. Discover new treatments targeting genetics and protein buildup to manage this devastating disease.

Different types of antisense oligonucleotide therapies, such as exosomes and nanoparticles, offering new hope in genetic medicine.

While no cure exists for PolyQ diseases like Huntington's, new breakthroughs, therapies, and research could change that.

Immunotherapy is advancing with new approaches like CAR-T cell therapy, antibody-drug conjugates, and even checkpoint inhibitors.

Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.

In this article, we speak with Nicole Stobart, Jeff Wilson, and Mark Schmidt, about how CAS is using authority constructs to index biological molecules.

Covalent inhibitors were once avoided due to negative side effects, but new drugs have changed the landscape.

More than 100 antibody-drug conjugates are in clinical trials. These therapeutics combine the targeting abilities of antibodies with the power of chemotherapy to change cancer treatment.

Since 2018, research interest in antibody-drug conjugates has increased exponentially, due to their potential in the fight against cancer.

We talk with Jefferson Parker of NullSet Informatics Solutions, about sequence analysis for drug discovery and the frontiers for AI in computational biology.

Induced-proximity target protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged recently.

We chat with Ben Taft, Sr. Director of Chemistry at Via Nova Therapeutics, about SAR studies and the possible frontiers for bioactivity data.

Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.

The ACE2 protein is the critical target for COVID-19 and other viral infections, and this knowledge has led to new therapeutics.

Exosomes could revolutionize drug delivery and diagnostics, but face isolation and purification challenges. This article explores recent trends in exosome research, focusing on their applications in drug delivery, diagnostics, and therapeutics. Discover how these unique particles are shaping the fut

The FDA can designate drug candidates as “breakthrough therapies” (breakthrough therapy designation or BTD) for certain drug candidates that demonstrate substantial improvement over available therapies on a clinically significant endpoint.

Bioorthogonal chemistry is a set of methods that use the chemistry of non-native functional groups to analyze biology in living organisms.

Learn more about cytokine storms and their role in both immunity and severe infection with COVID-19 and additional viral infections. This overviews emerging trends and insights on publications, milestones, and future applications to minimize the impact of cytokine adverse effects.

Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.

When mRNA (messenger RNA) vaccines are injected into a patient, tiny lipid vesicles transport mRNA molecules through the body fluids and merge with immune cells, called antigen-presenting cells (APCs).

Find out how companies improve their prediction accuracy, obtain Breakthrough Technology Status and shorten the development and review time of new drugs by leveraging CAS advanced machine learning methods.

This blog details the recently published CAS indicator of drug innovation based on the structural novelty of new molecular entities (NMEs) which may better assess innovativeness of new drugs.

Scientists are searching ways to stop the spread of COVID-19, and the ACE2 receptor is one of the most promising targets.

Bioorthogonal chemistry is a set of methods using the chemistry of non-native functional groups to explore and understand biology in living organisms.

This insight report explores innovative research and technologies that played crucial roles in Covid-19 vaccine development.

This insight report explores innovative research and technologies that played crucial roles in Covid-19 vaccine development.

Se calcula que en uno de cada cinco cánceres humanos se producen mutaciones de las proteínas RAS. Aunque en el pasado se consideraba inviable su uso como objetivos, en esta entrada analizamos los avances recientes en el campo de los inhibidores de RAS y las terapias emergentes.

The COVID pandemic revealed deficiencies in mask development and production. Innovation will be crucial in slowing the spread of new variants of the virus.

As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.

Targeted protein degradation is a novel and quickly expanding drug discovery strategy. It is a new way of utilizing disease-causing proteins to attack severe illnesses, which has the potential to be used among more serious illnesses, such as cancer or neurodegenerative diseases.

Artificial intelligence (AI) and machine learning have been growing exponentially over the last decade, but how has the field of Chemistry evolved with this emerging trend?

The use of RNA in therapeutics has the potential to revolutionize medicine. This white paper highlights the emerging trends in the industry.

Lipid nanoparticles play critical roles in mRNA vaccines for treating COVID-19, but their use is not new. Read about past, present, and future opportunities.

The last decade has seen a dramatic shift towards RNA-based medicine. Rapid success in developing lipid-RNA nanoparticles for COVID-19 mRNA vaccines, along with several approved drugs, has propelled RNA to the forefront of pharmaceutical research and development. Explore this revolutionary trend.

This white paper details the CAS Biomedical Knowledge Graph and shows how it was used in drug discovery for COVID-19.

Learn about the important functions of intrinsically disordered proteins and the key role they play in COVID-19 therapy.

This blog lists and discusses the common ingredients (both in the household and scientific contexts) as well as the unique ingredients used in the Covid-19 vaccines currently in use in the United States, and also addresses the dosage levels proposed for children under five years of age.

Omicron's significant evolution from the original COVID-19 virus raises concerns about reinfection and vaccine evasion. This variant could potentially bypass existing immunity, threatening global pandemic recovery efforts. Explore the potential societal and economic impacts of this new challenge.

The methodology behind CAS knowledge graphs enhances potential drug identification for COVID-19 treatment and other diseases.

The COVID-19 pandemic has motivated researchers across the globe to find effective drugs and therapeutics for treating the disease.

En los últimos años, la aplicación de la IA a la química ha crecido rápidamente. Si bien ha habido mucha publicidad sobre la IA utilizada de esta manera, no ha habido muchos análisis en profundidad sobre su uso y desarrollo en el campo de la química.

Lipid nanoparticles (LNPs) have emerged as promising vehicles to deliver a variety of therapeutics in the pharmaceutical industry. Liposomal drugs, based on an earlier version of LNPs, have already been approved and applied to medical practice.

This report reviews Covid-19 vaccine research, compares the underlying technologies, the use of adjuvants and delivery systems in their application, and provides a perspective on their future direction.

Artificial Intelligence may be hot right now, but the smart money is investing in data. See how CAS solutions can help.

Learn how machine learning procedures and CAS COVID-19 resources, including scientific insights, open access datasets and special reports are assisting in the research to fight against COVID-19.

To identify potential anti-SARS-CoV-2 therapeutics, CAS scientists are building machine-learning predictive models to identify novel drug candidates for the viral targets 3 chymotrypsin-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp).

In support of ongoing research efforts to identify additional drugs for COVID-19, a team of CAS scientists analyzed published scientific information and created a comprehensive report focusing on proteins involved in COVID-19 and potential corresponding drug candidates.

This report aids COVID-19 therapeutic research by summarizing protein targets and potential drug candidates. It includes bioassay and structure-activity relationship data from scientific and patent literature for COVID-19 and related viral infections. Explore key insights to support ongoing drug dev

A critical step in the race to develop treatments for COVID-19 is to gain a clear understanding of how the virus enters our cells. This insight will support development of targeted antiviral treatments focused on blocking that pathway.

To provide a better understanding and comparison of the diagnostic tests available in the fight against COVID-19, CAS has produced a report summarizing the basic principles of molecular and serological assays being used in diagnostic tests for SARS-CoV-2.

To support R&D on COVID-19, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection.